… factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the …
… a performance status according to Eastern Cooperative Oncology Group performance status
(ECOG) of 0–2 were enrolled in this multi-center prospective randomized phase III study in …
(ECOG) of 0–2 were enrolled in this multi-center prospective randomized phase III study in …
Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non–small-cell lung cancer
GV Scagliotti, U Pastorino, JF Vansteenkiste… - Journal of clinical …, 2012 - ascopubs.org
… Median age of all patients was 61.8 years, and 72% had an ECOG performance status of 0.
The percentage of males was significantly greater in the surgery alone arm (89% v 78%; P = .…
The percentage of males was significantly greater in the surgery alone arm (89% v 78%; P = .…
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients …
M Peeters, TJ Price, A Cervantes… - Journal of clinical …, 2010 - ascopubs.org
… Patients with mCRC, one prior chemotherapy regimen for mCRC, Eastern Cooperative
Oncology Group performance status 0 to 2, and available tumor tissue for biomarker testing were …
Oncology Group performance status 0 to 2, and available tumor tissue for biomarker testing were …
[HTML][HTML] A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients …
SH Park, DH Lim, TS Sohn, J Lee, DY Zang, ST Kim… - Annals of …, 2021 - Elsevier
… Eastern Cooperative Oncology Group (ECOG) performance status scores range from 0 to
5, with higher scores indicating greater disability. A score of 0 indicates no symptoms, and 1 …
5, with higher scores indicating greater disability. A score of 0 indicates no symptoms, and 1 …
Randomized phase II evaluation of carboplatin and CHIP in advanced transitional cell carcinoma of the urothelium
DL Trump, P Elson, S Madajewicz, SH Dickman… - The Journal of …, 1990 - Elsevier
… Randomization. To balance potential risk factors between the 2 treatments patients were
randomized … measurable versus evaluable disease, and performance status 0 or 1 versus 2 or 3…
randomized … measurable versus evaluable disease, and performance status 0 or 1 versus 2 or 3…
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma
… performance status, and tumor measurement were performed within 4 weeks before
randomization. … (CEA) were obtained within 2 weeks of randomization. CBC, serum chemistry, and …
randomization. … (CEA) were obtained within 2 weeks of randomization. CBC, serum chemistry, and …
Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.
AP Chahinian, K Antman, M Goutsou… - Journal of clinical …, 1993 - ascopubs.org
… a performance status of 0 to 2 by CALGB criteria, and no prior chemotherapy. Central pathology
review was performed. Randomization … Good performance status (0 or 1) was associated …
review was performed. Randomization … Good performance status (0 or 1) was associated …
[HTML][HTML] … ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase …
RJ Van Soest, AJ Templeton, FE Vera-Badillo… - Annals of …, 2015 - Elsevier
… Associations of dNLR and duration of initial ADT with overall survival (OS) were evaluated
by multivariable Cox regression analysis in the training set stratified for performance status …
by multivariable Cox regression analysis in the training set stratified for performance status …
One versus three fractions of stereotactic body radiation therapy for peripheral stage I to II non-small cell lung cancer: a randomized, multi-institution, phase 2 trial
AK Singh, JA Gomez-Suescun, KL Stephans… - International Journal of …, 2019 - Elsevier
… This randomized phase 2 study demonstrated that 30 Gy in 1 fraction was equivalent to 60
… aged 18 years or older with a Zubrod performance status score of 0 to 2, deemed medically …
… aged 18 years or older with a Zubrod performance status score of 0 to 2, deemed medically …
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell …
… IFN-α treatment were Karnofsky performance status less than 80%, … The patients in this
CCI-779 phase II study were … of 1, rather than Karnofsky performance status less than 80%, and …
CCI-779 phase II study were … of 1, rather than Karnofsky performance status less than 80%, and …